# EDGAR Filing Document

**Accession Number:** 0000874710
**File Stem:** 0001104659-23-021237
**Filing Date:** 2023-2
**Character Count:** 6979
**Document Hash:** 178b075af7bd551611f58b7d2f795c64
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-021237.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001104659-23-021237

**CONFORMED SUBMISSION TYPE**: NT 10-Q

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**EFFECTIVENESS DATE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALLIED HEALTHCARE PRODUCTS INC
- **CENTRAL INDEX KEY:** 0000874710
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **IRS NUMBER:** 231370721
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** NT 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19266
- **FILM NUMBER:** 23626384

**BUSINESS ADDRESS:**
- **STREET 1:** 1720 SUBLETTE AVE
- **CITY:** ST LOUIS
- **STATE:** MO
- **ZIP:** 63110
- **BUSINESS PHONE:** 3147712400

**MAIL ADDRESS:**
- **STREET 1:** 1720 SUBLETTE AVENUE
- **CITY:** ST LOUIS
- **STATE:** MO
- **ZIP:** 63110

UNITED STATES SECURITIES AND EXCHANGE COMMISSION<br> Washington, D.C. 20549   <br> FORM 12b-25 <u> SEC FILE NUMBER 000-19266</u> <br> NOTIFICATION OF LATE FILING <u> CUSIP NUMBER 019222 10 8 </u>

(Check one): □ Form 10-K □ Form 20-F □ Form 11-K x Form 10-Q □ Form 10-D □ Form N-SAR

For Period Ended: <u>December 31, 2022</u> 

◻ Transition Report on Form 10-K

◻ Transition Report on Form 20-F

◻ Transition Report on Form 11-K

◻ Transition Report on Form 10-Q

◻ Transition Report on Form N-SAR

For the Transition Period Ended: _________________

&nbsp;&nbsp; *Read Instruction (on back page) Before Preparing Form. Please Print or Type.*<br> **Nothing in this form shall be construed to imply that the Commission has verified any information contained herein** <br>

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

**PART I — REGISTRANT INFORMATION**

Allied Healthcare Products, Inc.

Full Name of Registrant

Former Name if Applicable

1720 Sublette Avenue

Address of Principal Executive Office (Street and Number)

St. Louis, Missouri 63110

City, State and Zip Code

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

⌧ (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form prescribed due date; or the subject quarterly report or N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the transition report on Form 10-Qorsubject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or
other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III — NARRATIVE**

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

As discussed in more detail below, Allied Healthcare Products, Inc. (the "Company" or "Allied") experienced significant losses and negative cash flow during the quarter and six month period ended December 31, 2022. In addition, as previously disclosed, the Company has terminated many of the employees of its headquarters and instituted severe cost cutting measures and announced its plan to sell all or substantially all of the assets of the Company.

As a result, the Company is unable to file its Quarterly Report on Form 10-Q for the period ended December 31, 2022 by the prescribed due date without unreasonable effort and expense.

**PART IV — OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to
this notification

<u>Daniel C. Dunn</u> <u> 314</u> <u>771-2400</u> <br> (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30
of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file
such report(s) been filed? If answer is no, identify report(s).

Yes ⌧ No ◻

(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the
subject report or portion thereof ?

Yes ⌧ No ◻

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

The Company experienced a loss of $1.0 million before taxes for the quarter, compared to a loss of $1.2 million before taxes for the same period of fiscal year 2022. For the six months ended December 31, 2022, the Company experienced a loss of $2.6 million before taxes, compared to $2.1 million before taxes for the same period in fiscal year 2022.

Net sales for the quarter of $6.2 million were $0.6 million or 8.8% lower than the comparable quarter in fiscal 2022. Domestically, sales decreased by $0.4 million while international sales, which represented 23.7% of the quarter's sales, were $0.2 million lower. Sales for the quarter continued to be negatively impacted by delays in obtaining inputs, production delays, and a staffing shortage in our manufacturing operation.

Net sales for the six months ended December 31, 2022 of $11.4 million were $2.8 million or 19.7% lower than the same period in fiscal 2022. Domestically, sales decreased by $2.3 million, while international sales, which represented 23.1% of the period sales, were $0.5 million lower.

During the six months ended December 31, 2022 the Company used $1.6 million of cash in operating activities.

Allied Healthcare Products, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date | February 14, 2023 | By | /s/ Daniel C. Dunn |
|  |  | Name | Daniel C. Dunn |
|  |  | Title | Vice President, Chief Financial Officer, Secretary |

---

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.